I have invested in dividends for 10 years—These are the blue-chip dividend payers I swear by in July

Dividend Stocks: Your Wealth-Building Shield for July

With economic clouds gathering from tariff uncertainties and economic doubts amid Federal Reserve interest rate policy, dividend stocks shine as a beacon for investors craving stability and growth. 

These companies, known for sharing profits through consistent payouts, offer a dual promise: reliable income to weather market volatility and the potential for long-term wealth through compounding. 

Historically, dividend payers have delivered 9.2% annualized returns from 1973 to 2024, outpacing non-payers by over 2-to-1, with lower volatility, according to analysis by Hartford Funds. Their steady cash flows act as a buffer against bear market dips, which average 35% during declines, while enabling reinvestment for exponential growth.

Unlike high-yield traps that risk dividend cuts, quality dividend stocks — backed by strong cash flows and sustainable payout ratios — provide a hedge against economic uncertainty. As markets brace for potential turbulence, two blue-chip dividend stocks stand out as my go-to picks for reliable income and capital appreciation in July.

Chevron (CVX): A Dividend Powerhouse with Energy Durability

Chevron (NYSE:CVX) is a global energy titan, a blue-chip dividend stock with a rock-solid track record and robust growth potential. With a $260 billion market cap, Chevron’s integrated operations span oil, gas, and renewables, ensuring diversified revenue streams. 

Its first-quarter earnings produced $3.5 billion in net income, down 36% year-over-year, but still driven by strong Permian Basin production and a 8% increase in natural gas output. Chevron’s 4.5% dividend yield, with a $1.71 quarterly payout, is backed by 38 years of consecutive increases, earning it Dividend Aristocrat status. The payout ratio of 67% signals sustainability, supported by $3.7 billion in free cash flow. 

Chevron’s investments in carbon capture and hydrogen, like its Bayou Bend project, position it for a future energy transition, while its $13 billion Hess acquisition (pending resolution of a dispute with ExxonMobil (NYSE:XOM)) boosts upstream growth. Analysts project 7% long-term EPS growth , with a $163 per share price target, implying 10% upside.

Risks include oil price volatility, with Brent crude at $76 posing margin pressure if prices dip, and environmental litigation that could strain costs. Chevron’s forward P/E of 18x, somewhat above the sector’s 13x, suggests a premium, and tariff-driven cost hikes may challenge refining margins. Despite these risks, Chevron’s scale, low debt-to-equity, and a 2023 $75 billion buyback program ensure potency, though it will cut back on stock buybacks this year due to lower oil prices. 

For investors, Chevron’s stable dividends and energy transition bets make it a blue-chip anchor for long-term income and modest capital appreciation.

UnitedHealth Group (UNH): A Healthcare Dividend Stalwart

UnitedHealth Group (NYSE:UNH), with a $276 billion market cap, is a blue-chip dividend stock blending healthcare stability with growth. As the largest U.S. health insurer, UNH serves 153 million members through its Optum and insurance segments, driving first-quarter revenue of $109.6 billion, up 10% year-over-year. Its 2.8% dividend yield, with a $2.10 quarterly payout, has grown for 15 years, backed by a 52% payout ratio and $4.6 billion in free cash flow. 

UNH’s Optum Health unit, focusing on value-based care, grew 4.6% in Q1, leveraging artificial intelligence for cost efficiencies. Analysts forecast 2% long-term earnings growth , with a $386 price target (suggesting 27% upside). 

UNH’s diversified model, spanning insurance, pharmacy benefits, and care delivery, shields it from sector disruptions, while its 18% return on equity underscores financial strength.

It does face some significant immediate risks, including regulatory scrutiny and potential Medicare Advantage rate cuts that could impact margins. Cybersecurity threats, like the 2024 Change Healthcare breach, cost $1.6 billion, and future incidents could dent trust. It has also run into a string of bad press recently, such as a rare earnings miss, questions about its claims denial process following the assassination of its CEO in December, the abrupt resignation of his replacement, and a purported DOJ civil fraud probe into UNH’s Medicare billing practices (which it denies).

UNH’s forward P/E of 13x, well below the healthcare sector’s 17x and its five-year average of 20x, reflects it is undervalued, while a non-GAAP PEG ratio of 2 suggests fair growth pricing. Medical costs are expected to rise 7% in 2025, pressuring profitability, but UNH’s scale helps mitigate this. A remaining authorization to repurchase up to 27 million shares and a low debt-to-equity ratio bolster its stability.

For investors, UNH’s consistent dividends, AI-driven innovation, and defensive healthcare exposure make it a top blue-chip pick for income and steady growth. Trading at a level not seen since 2021, UnitedHealth Group offers an opportunity to buy a quality company at an attractive price. 

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.